• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 28Characteristics of pioglitazone active-control trials with sulfonylureas in adults with type 2 diabetes

Author, year
Quality
Sample size (N)
Follow-up (weeks)
Age (years) (SD)a
% Femalea
% Whitea
% Hispanica
Other population characteristics
InterventionCombination therapy
Agarwal 2005125
Fair
44
16
67 (8.5)
0
NR
NR
68% on insulin at baseline;
All had overt diabetic nephropathy
Glipizide: start 5 mg daily; mean maximal dosage 41 mg daily

Pio: start 15 mg daily, mean maximal dosage 19 mg daily
Combined with various oral hypoglycemic agents or insulin
Basu 2006126
Fair
19
12
56 (2)
33
NR
NR
Glipizide: 10 mg daily (median dose)

Pio: 45 mg daily
None
Mazzone 2006127
Fair
458
72
59.9 (8.2)
37
NR
NR
Newly diagnosed on any therapy
Pio 15–45 mg daily

Glimepiride 1–4 mg daily
Add-on metformin or insulin as needed (12%–13% took insulin during study)
Nissen 2008128
Multinational
Fair
360
78
59.7 (9.1)
34
81
NR
At least 1 angiographic stenosis with at least 20% narrowing
Pio 15–45 mg daily
Glimepiride 1–4 mg daily
Added to ongoing diabetic treatment (metformin in 63 to 65%; insulin in 18 to 23%)
Papathanassiou 2009129
Greece
Fair
28
26
63.6 (7.3)
79
NR
NR
Treated with metformin only
Pio 30 mg daily
Glimepiride 4 mg daily
Added to metformin
Perriello 2006130
Fair
283
52
59 (assume SD 7)
36
NR
NR
HbA1c>7.5%
Pio 30–45 mg daily

Gliclazide 80–320 mg daily
Appears to be monotherapy (some patients on 1 oral agent prior to study)
Pfutzner 2005131
Fair
179
26
63.0 (7.4)
38
NR
NR
Failed various oral agents; no prior TZD use
Pio 24 mg daily

Glimepiride 1–6 mg daily and TZDs with glimepiride
Other oral agents permitted in both groups, except metformin with pio
Teramoto 2007133
Fair
92
24
56.4 (10.5)
24
NR
NR
Triglycerides 150–500 mg/dL
Pio 15–30 mg daily

Glibenclamide 1.25–2.5 mg daily
None
Umpierrez 2006134
Fair
210
26
51.6 (11.8)
45
NR
NR
Inadequately controlled on metformin monotherapy
Pio 30–45 mg daily
Glimepiride 2–8 mg daily
Add-on to metformin therapy
Yamanouchi 2005135
Japan
Fair
114
52
Metformin group:
54.7 (9.8)
49
NR
NR
Not on oral agents previously
Pio 30–45 mg daily

Metformin 750 mg daily

Glimepiride 1.0–2.0 mg daily
None

Abbreviations: NR, not reported; Pio, pioglitazone; SD, standard deviation; SE, standard error; TZD, thiazolidinedione.

a

Data shown are mean (SD) unless otherwise indicated.

Data shown are mean (SD) unless otherwise indicated.

From: Results

Cover of Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations
Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report [Internet].
Jonas D, Van Scoyoc E, Gerrald K, et al.
Portland (OR): Oregon Health & Science University; 2011 Feb.
Copyright © 2011, Oregon Health & Science University.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.